What Apogee Therapeutics does

Apogee Therapeutics is a clinical-stage biotechnology company developing novel antibody therapeutics for immunological and inflammatory (I&I) disorders. Founded in 2022 as a spinout from Paragon Therapeutics and led by veterans of BridgeBio, the company went public on NASDAQ under ticker APGE in December 2024 and is headquartered in Waltham, Massachusetts with an additional office in San Francisco. Its pipeline is anchored by zumilokibart (formerly APG777), a subcutaneous half-life extended monoclonal antibody targeting IL-13 that has generated positive Phase 2 Part B 16-week data in moderate-to-severe atopic dermatitis (approximately two-thirds of patients achieving significant skin clearance at 16 weeks) and is also being advanced in asthma and eosinophilic esophagitis. The pipeline additionally includes combination programs APG279 (IL-13 plus OX40L) and APG273 (IL-13 plus TSLP), as well as APG808 targeting IL-4Rα, all leveraging the company's shared antibody engineering platform.

Apogee's underlying technology is an FcRn-mediated half-life extension platform that engineers antibodies to bind better to the neonatal Fc receptor, sparing them from degradation and enabling subcutaneous dosing every three to six months versus the bi-weekly or monthly dosing typical of current standard-of-care biologics such as Dupixent. The company has executed a 'pipeline-in-a-product' strategy, applying the lead asset across multiple I&I indications and pursuing both monotherapy and combination approaches to broaden inflammation coverage. Clinical development currently spans the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.

As a pre-revenue biotech, Apogee generates no product sales. Its business model depends on future commercialization through traditional pharmaceutical distribution and field sales teams targeting dermatologists, pulmonologists, and gastroenterologists, supported by a newly appointed Chief Commercial Officer. To date the company has financed operations primarily through capital markets: a $149M Series B (December 2022), a $483M upsized public offering (March 2024), a $345M public offering (October 2025), a $403M public offering (March 2026), and a strategic financing collaboration with Blackstone Life Sciences worth up to $1.3 billion (May 2026). In June 2026, AbbVie announced a definitive agreement to acquire Apogee for approximately $10.9 billion in cash, expected to close in Q3 2026 subject to shareholder and regulatory approvals.

Name

Apogee Therapeutics

Legal name

Apogee Therapeutics, Inc.

Website

https://apogeetherapeutics.com

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

251–500 employees

Short description

Apogee Therapeutics is a clinical-stage biotechnology company developing half-life extended monoclonal antibodies for atopic dermatitis, asthma, COPD, and eosinophilic esophagitis. Founded in 2022 as a Paragon Therapeutics spinout, the company went public on NASDAQ in 2024 and is subject to a pending AbbVie acquisition.

Ownership category

akta.pro rank

Product category

Biologics and monoclonal antibody therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Clinical-stage biotechnology
• Monoclonal antibody therapeutics
• Inflammatory disease biologics
• Atopic dermatitis treatment
• Antibody engineering platform

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Biopharmaceutical Development: Clinical-stage biotechnology company with no approved products or revenue. Developing novel biologic therapies for inflammatory and immunology conditions. Revenue will be generated through product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Apogee Therapeutics is developing a pipeline of novel, subcutaneous, half-life extended monoclonal antibody therapeutics targeting well-established immunology and inflammation pathways (IL-13, OX40L, TSLP, IL-4Rα) for atopic dermatitis, asthma, COPD, and eosinophilic esophagitis. Its lead asset, Zumilokibart (APG777), targets IL-13 with dosing every 3-6 months versus bi-weekly dosing of standard-of-care biologics. The company is also advancing combination therapies APG279 (IL-13 + OX40L) and APG273 (IL-13 + TSLP), plus APG808 (IL-4Rα).

Product overview

Apogee Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel antibody therapeutics for immunological and inflammatory diseases. The company's core product is Zumilokibart (APG777), a half-life extended monoclonal antibody targeting IL-13, which has completed Phase 2 for atopic dermatitis. The company is pursuing a 'pipeline-in-a-product' strategy with Zumilokibart across multiple indications including atopic dermatitis, asthma, and eosinophilic esophagitis. Additional programs include combination therapies APG279 (IL-13 + OX40L) and APG273 (IL-13 + TSLP), as well as APG808 (IL-4Rα). All programs leverage advanced antibody engineering to optimize half-life and achieve less frequent dosing compared to existing treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• Zumilokibart (APG777) Novel, subcutaneous half-life extended monoclonal antibody targeting IL-13 for the potential treatment of atopic dermatitis (with positive Phase 2 Part B 16-week data), as well as asthma and eosinophilic esophagitis. Designed for subcutaneous dosing every 3 or 6 months versus bi-weekly dosing for current standard-of-care biologics.
• APG279 Combination therapy comprising APG777 (zumilokibart) plus APG990, designed to address multiple immune signaling intervention points through dual inhibition of IL-13 and OX40L for potential first-in-class combination treatment in atopic dermatitis and other I&I indications.
• APG273 Combination therapy comprising APG777 (zumilokibart) plus APG333, targeting IL-13 and TSLP for asthma and COPD, designed to address both central and local drivers of obstructive airway disease and potentially break through the efficacy ceiling observed with monotherapies.
• APG808 Anti-IL-4Rα monoclonal antibody incorporating Apogee's half-life extension technology for the potential treatment of asthma, demonstrating safety and extended half-life in Phase 1 studies.

Quantifiable outcome

• Phase 2 APEX Part B: Approximately two-thirds of patients achieved significant skin clearance at 16 weeks
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• AbbViecoreOthers · 22 June 2026AbbVie announced definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in cash ($135.11 per share). The acquisition aims to strengthen AbbVie's immunology portfolio with Apogee's pipeline including zumilokibart for atopic dermatitis and asthma. Deal expected to close Q3 2026 pending shareholder and regulatory approvals.
• Paragon TherapeuticscoreStrategic or Co-development Partner · 7 December 2022Apogee acquired drug targets from Paragon Therapeutics at founding. Company spun out from Paragon with access to proprietary antibody engineering technology and targets.

Scale indicators5 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Arcutis Biotherapeutics: Clinical-stage immunology biotech focused on atopic dermatitis and other inflammatory skin diseases, directly overlapping with Apogee's lead AD indication and the same physician specialty channel.
• AnaptysBio: Clinical-stage antibody developer focused on immunology and inflammation targets including IL-36, IL-33, and PD-1, with a comparable business model of developing novel mAbs for I&I indications.
• MoonLake Immunotherapeutics: Clinical-stage immunology company developing nanobody therapies for inflammatory skin and joint diseases, sharing Apogee's focus on differentiated biologics for I&I indications.
• Spyre Therapeutics: Clinical-stage biotech developing engineered antibodies for inflammatory bowel disease and other I&I indications, with overlapping leadership and a similar antibody-engineering platform approach.

Emerging players

• Q32 Bio: Early-stage biotech developing novel biologics for autoimmune and inflammatory diseases, with a similar therapeutic-area focus to Apogee but earlier-stage pipeline assets.
• Oruka Therapeutics: Clinical-stage immunology company developing long-acting IL-23 antibodies for inflammatory skin diseases, sharing Apogee's half-life extension philosophy and AD indication focus.

Broad incumbents

• Regeneron Pharmaceuticals: Large biopharma and co-developer of Dupixent (the dominant AD biologic), making it the most direct commercial competitive incumbent to Apogee's lead asset.
• Eli Lilly: Global biopharma developing lebrikizumab (anti-IL-13) and other immunology assets, a key head-to-head competitor referenced in Apogee's preclinical positioning.
• AbbVie: Global biopharma and announced acquirer of Apogee; AbbVie's immunology franchise (Skyrizi, Rinvoq, Humira) provides the commercial engine that will deploy zumilokibart post-approval.

Others

• AbCellera Biologics: Antibody discovery platform company whose technology stack overlaps with Apogee's antibody engineering approach, though AbCellera operates as a discovery engine rather than a clinical developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apogee Therapeutics